Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery of the First Orally Available, Selective KNa1.1 Inhibitor: In Vitro and In Vivo Activity of an Oxadiazole Series

9 Mar 2021

Abstract excerpt

The gene KCNT1 encodes the sodium-activated potassium channel K Na 1.1 (Slack, Slo2.2). Variants in the KCNT1 gene induce a gain-of-function (GoF) phenotype in ionic currents and cause a spectrum of intractable neurological disorders in infants and children, including epilepsy of infancy with migrating focal seizures (EIMFS) and autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE). Effective treatment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epilepsy research and treatment
Share to Ion channel regulation and function
Share to Ion Transport and Channel Regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33859800
DOI: 10.1021/acsmedchemlett.0c00675

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery of the First Orally Available, Selective KNa1.1 Inhibitor: In Vitro and In Vivo Activity of an Oxadiazole SeriesPMID 33859800Read ↗

Discovery of Potent and Selective Blockers Targeting the Epilepsy-Associated KNa1.1 Channel.Semantic proximity Read ↗

Large-Scale Structure-Based Virtual Screening Identifies Diverse K <sub>Na</sub> 1.1 (KCNT1) Potassium Channel InhibitorsSemantic proximity Read ↗

New use for an old drug: quinidine in KCNT1-related epilepsy therapy.Semantic proximity Read ↗

Identification of new KCNT1-epilepsy drugs by <i>in silico,</i> cell and <i>Drosophila</i> modellingSemantic proximity Read ↗

Identification of New KCNT1-Epilepsy Drugs by In Silico, Cell, and Drosophila Modeling.Semantic proximity Read ↗

Approaches for the discovery of drugs that target K Na 1.1 channels in KCNT1-associated epilepsy.Semantic proximity Read ↗

Targeting KNa1.1 channels in KCNT1-associated epilepsy.Semantic proximity Read ↗

Electrophysiological characterization of human KCNT1 channel modulators and the therapeutic potential of hydroquinine and tipepidine in KCNT1 mutation-associated epilepsy mouse model.Semantic proximity Read ↗

Quinidine therapy for West syndrome with KCNTI mutation: A case report.Semantic proximity Read ↗

Na <sub>V</sub> 1.6 inhibition drives the efficacy of voltage-gated sodium channel inhibitors to prevent electrically induced seizures in both wild type and <i> Scn8a <sup>N1768D/+</sup> </i> gain-of-function miceSemantic proximity Read ↗

Quinidine Therapy for Lennox-Gastaut Syndrome With KCNT1 Mutation. A Case Report and Literature ReviewSemantic proximity Read ↗

KNa1.1 gain-of-function preferentially dampens excitability of murine parvalbumin-positive interneurons.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.